MyMyelomaTeam

Certain treatments for multiple myeloma, such as Kyprolis (carfilzomib) and dexamethasone, can increase the risk of cardiovascular complications. Carfilzomib, in particular, has been shown to cause a higher risk of cardiac events, including heart damage, arrhythmia, and heart failure. Adding Sarclisa (isatuximab-irfc) to Show Full Answer

Certain treatments for multiple myeloma, such as Kyprolis (carfilzomib) and dexamethasone, can increase the risk of cardiovascular complications. Carfilzomib, in particular, has been shown to cause a higher risk of cardiac events, including heart damage, arrhythmia, and heart failure. Adding Sarclisa (isatuximab-irfc) to your regimen may also contribute to these effects, as it can cause infusion-related reactions and other side effects.

If you experience a significant increase in your resting heart rate, it's important to discuss this with your healthcare provider to ensure proper management and monitoring.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Understanding Heart Disease and Myeloma Treatment | MyMyelomaTeam

Member Spotlight: No Expiration Date | MyMyelomaTeam